- Year founded
- 1999
- Country of origin
- Belgium
- HQ country
- Belgium
- Average deal value
- Login to see more
- Total deal value
- Login to see more
- Company industry
- Medical & Biotech
- M&A expertise
- -
- Industry expertise
- -
Galapagos is a clinical stage biotech company focused on developing novel medicines. Galapagos’ most advanced candidate drug GLPG0634 shows excellent safety and efficacy in rheumatoid arthritis patients and is fully proprietary to Galapagos. With GLPG0634, Galapagos demonstrates its capabilities in developing novel medicines for difficult to cure diseases.
Latest deals
Alfasigma acquires Jyseleca business from Galapagos
30-10-2023
€ 170 million
